StockData
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$271.19−0.54 (-0.20%)

Close on Nov 17, 2026Market cap $16.81BP/E 22.3Yield –

Ascendis Pharma A/S operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ascendis Pharma A/S's operating cash flow for the twelve months ending Jun 30, 2026 was €349.51M. For fiscal 2025 it was €53.90M. The highest annual figure on record is €53.90M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025€53.90M–
FY2024Dec 31, 2024-€306.20M–
FY2023Dec 31, 2023-€467.36M–
FY2022Dec 31, 2022-€495.70M–
FY2021Dec 31, 2021-€417.65M–
FY2020Dec 31, 2020-€271.55M–
FY2019Dec 31, 2019-€175.94M–
FY2018Dec 31, 2018-€138.80M–
FY2017Dec 31, 2017-€95.10M–
FY2016Dec 31, 2016-€60.18M–
FY2015Dec 31, 2015-€43.47M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€281.68M–
Q1 FY2026Mar 31, 2026-€7.72M–
Q4 FY2025Dec 31, 2025€73.40M–
Q3 FY2025Sep 30, 2025€2.15M–
Q2 FY2025Jun 30, 2025-€7.34M–
Q1 FY2025Mar 31, 2025-€14.31M–
Q4 FY2024Dec 31, 2024-€87.18M–
Q3 FY2024Sep 30, 2024-€56.13M–
Q2 FY2024Jun 30, 2024-€61.31M–
Q1 FY2024Mar 31, 2024-€101.58M–
Q4 FY2023Dec 31, 2023-€42.47M–
Q3 FY2023Sep 30, 2023-€124.72M–
Q2 FY2023Jun 30, 2023-€153.13M–
Q1 FY2023Mar 31, 2023-€147.04M–
Q4 FY2022Dec 31, 2022-€141.69M–
Q3 FY2022Sep 30, 2022-€98.83M–
Q2 FY2022Jun 30, 2022-€124.39M–
Q1 FY2022Mar 31, 2022-€130.79M–
Q4 FY2021Dec 31, 2021-€123.31M–
Q3 FY2021Sep 30, 2021-€97.52M–
Q2 FY2021Jun 30, 2021-€115.20M–
Q1 FY2021Mar 31, 2021-€81.62M–
Q4 FY2020Dec 31, 2020-€90.33M–
Q3 FY2020Sep 30, 2020-€57.82M–
Q2 FY2020Jun 30, 2020-€56.61M–
Q1 FY2020Mar 31, 2020-€66.79M–
Q4 FY2019Dec 31, 2019-€49.24M–
Q3 FY2019Sep 30, 2019-€59.95M–
Q2 FY2019Jun 30, 2019-€5.89M–
Q1 FY2019Mar 31, 2019-€60.86M–
Q4 FY2018Dec 31, 2018-€35.56M–
Q3 FY2018Sep 30, 2018-€46.39M–
Q2 FY2018Jun 30, 2018-€20.11M–
Q1 FY2018Mar 31, 2018-€36.74M–
Q4 FY2017Dec 31, 2017-€24.16M–
Q3 FY2017Sep 30, 2017-€25.78M–
Q2 FY2017Jun 30, 2017-€23.92M–
Q1 FY2017Mar 31, 2017-€21.25M–

More Ascendis Pharma A/S figures

See a number that looks wrong?